Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MET | P08581 | 8/20 | 0.38 |
| ▸ | RIPK3 | Q9Y572 | 5/20 | 0.38 |
| ▸ | AXL | P30530 | 5/20 | 0.35 |
| ▸ | TYRO3 | Q06418 | 4/20 | 0.35 |
| ▸ | F10 | P00742 | 1/20 | 0.35 |
| ▸ | MERTK | Q12866 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | RIPK2 | O43353 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10278669 | 0.82 | MET (0.38) | METRIPK3AXLTYRO3F10 | |
| SCHEMBL14892188 | 0.80 | MET (0.37) | METRIPK3AXLTYRO3F10 | |
| SCHEMBL14892798 | 0.80 | MET (0.37) | METRIPK3AXLTYRO3F10 | |
| SCHEMBL1911277 | 0.79 | MAPT (0.37) | — | |
| SCHEMBL1911293 | 0.79 | PIM1 (0.37) | MET | |
| SCHEMBL1911219 | 0.77 | MAPT (0.37) | — | |
| SCHEMBL10278595 | 0.74 | GSK3B (0.54) | — | |
| SCHEMBL1910956 | 0.71 | PIM1 (0.64) | — | |
| SCHEMBL1911216 | 0.69 | PIM1 (0.63) | — | |
| SCHEMBL1911275 | 0.69 | CYP3A4 (0.58) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2012004217-A1 | CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS | NOVARTIS AG (CH) | 2012-01-12 | — | — | WO | disclosed |